Epilogy – Epidemiology and evaluation of therapeutics in dermatology and immune-mediated inflammatory diseases

Epilogy

Epidemiology and evaluation of therapeutics in dermatology and immune-mediated inflammatory diseases

The Epilogy team aims to provide evidence-based and up-to-date information on therapeutic assessment and therapeutic strategy for patients with chronic dermatoses and/or immune-mediated inflammatory disorders (IMIDs).

Presentation & Objectives

Our research focuses on patients with IMIDs, including psoriasis, atopic dermatitis and hidradenitis
suppurativa (...)

Organization & Members

The research team is structured around a multidisciplinary core of drug-specialist physicians,
clinicians (...)

Expertise

Team members are strongly involved in national referral centers of rare diseases, including: National referral center (...)

Data Sources

We conduct nationwide, population-based cohort study using the French national health data system (Système National des Données de Santé) (...)

PhD Candidates

Post-Doc

Thesis Defense

New
Publications

Phytophotodermatitis: An under-recognized diagnostic pitfall in chemical burn

Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System

Antibiotic Use and the Persistence of Biologic Therapies in Patients With Psoriasis

Get in touch with us!

Epilogy
Faculty of Health – Henri-Mondor University Hospital (AP-HP)
Mondor Institute, Inserm U955
8 rue du Général Sarrail - 94010 Créteil - France
Tel.: +(33) 1 49 81 25 01 - E-mail: contact@epilogy.org